title: Protective effects of sinapic acid on lysosomal dysfunction in isoproterenol induced myocardial infarcted rats.
abstract: In the pathology of myocardial infarction, lysosomal lipid peroxidation and resulting enzyme release play an important role. We evaluated the protective effects of sinapic acid on lysosomal dysfunction in isoproterenol induced myocardial infarcted rats. Male Wistar rats were treated with sinapic acid (12 mg/kg body weight) orally daily for 10 days and isoproterenol (100 mg/kg body weight) was injected twice at an interval of 24 h (9th and 10th day). Then, lysosomal lipid peroxidation, lysosomal enzymes in serum, heart homogenate, lysosomal fraction and myocardial infarct size were measured. Isoproterenol induced myocardial infarcted rats showed a significant increase in serum creatine kinase-MB and lysosomal lipid peroxidation. The activities of β-glucuronidase, β-galactosidase, cathepsin-B and D were significantly increased in serum, heart and the activities of β-glucuronidase and cathepsin-D were significantly decreased in lysosomal fraction of myocardial infarcted rats. Pre-and-co-treatment with sinapic acid normalized all the biochemical parameters and reduced myocardial infarct size in myocardial infarcted rats. In vitro studies confirmed the free radical scavenging effects of sinapic acid. The possible mechanisms for the observed effects are attributed to sinapic acid's free radical scavenging and membrane stabilizing properties. Thus, sinapic acid has protective effects on lysosomal dysfunction in isoproterenol induced myocardial infarcted rats.
authors.affiliation: Department of Biochemistry and Biotechnology, Annamalai University, Annamalai Nagar 608002, Tamil Nadu, India.
authors.forename: Subhro Jyoti
authors.initials: SJ
authors.lastname: Roy
authors.forename: Ponnian
authors.initials: P
authors.lastname: Stanely Mainzen Prince
mesh_terms: D000818:Animals; D002316:Cardiotonic Agents / Q000494:pharmacology*; D002401:Cathepsin B / Q000378:metabolism; D002402:Cathepsin D / Q000378:metabolism; D003373:Coumaric Acids / Q000494:pharmacology*; D052279:Creatine Kinase, MB Form / Q000097:blood; D004305:Dose-Response Relationship, Drug; D016166:Free Radical Scavengers / Q000494:pharmacology; D005966:Glucuronidase / Q000378:metabolism; D007545:Isoproterenol / Q000633:toxicity; D015227:Lipid Peroxidation / Q000187:drug effects; D008247:Lysosomes / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D009203:Myocardial Infarction / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009206:Myocardium / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D001616:beta-Galactosidase / Q000378:metabolism
chemical_list: D002316:Cardiotonic Agents; D003373:Coumaric Acids; D016166:Free Radical Scavengers; C073734:sinapinic acid; D052279:Creatine Kinase, MB Form; D001616:beta-Galactosidase; D005966:Glucuronidase; D002401:Cathepsin B; D002402:Cathepsin D; D007545:Isoproterenol